State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.
J Pharm Biomed Anal. 2019 Jan 30;163:64-77. doi: 10.1016/j.jpba.2018.09.049. Epub 2018 Sep 29.
Cardiac hypertrophy (CH) is a major risk factor for many serious heart diseases. Sustained CH is catastrophic, resulting in cardiac dysfunction that eventually leads to heart failure (HF). Baoyuan decoction (BYD) is a famous traditional Chinese medicine (TCM) formula for supplementing and reinforcing Qi, clinically used for the treatment of cardiovascular diseases (CVDs). However, the therapeutic effects of BYD on CH remain unidentified. We herein investigated the effect of BYD on isoproterenol (ISO)-induced CH in rats and the underlying mechanisms by comprehensive pharmacodynamics and H NMR-based dynamic metabolomics analysis of the plasma and urine samples. Results showed that BYD treatment markedly attenuated ISO-induced CH as evidenced by decreasing the left ventricular wall thickness, pathological cardiomyocyte hypertrophy, myocardial collagen fiber deposition and apoptosis, and plasma natriuretic peptide levels. Multivariate trajectory analysis revealed that the BYD treatment could restore the CH-disturbed plasma and urinary metabolite profiles towards the normal metabolic status featuring with a time-dependent tendency. Moreover, the key metabolic alterations in CH rats at different BYD-treated time stages involved energy metabolism, oxidative stress responses, amino acid metabolism, and gut microbiota metabolism. Of particularly, the significant roles of BYD for treating CH lie in the improvement of cardiac energy generation and antioxidant capacity. Our investigation provides a holistic view of BYD for therapeutic intervention of CH through monitoring of the dynamic metabolic changes and the results indicate that BYD may be applied as a potential agent for treating CH.
心肌肥厚(CH)是许多严重心脏病的主要危险因素。持续的 CH 是灾难性的,导致心脏功能障碍,最终导致心力衰竭(HF)。保元汤(BYD)是一种著名的中药(TCM)配方,用于补充和增强气,临床上用于治疗心血管疾病(CVDs)。然而,BYD 对 CH 的治疗效果仍不清楚。我们在此通过对血浆和尿液样本的综合药效学和 H NMR 基于动态代谢组学分析,研究了 BYD 对异丙肾上腺素(ISO)诱导的 CH 大鼠的作用及其潜在机制。结果表明,BYD 治疗显著减弱 ISO 诱导的 CH,表现为左心室壁厚度降低、病理性心肌细胞肥大、心肌胶原纤维沉积和凋亡以及血浆利钠肽水平降低。多变量轨迹分析显示,BYD 治疗可将 CH 紊乱的血浆和尿液代谢谱恢复到正常代谢状态,具有时间依赖性趋势。此外,CH 大鼠在不同 BYD 治疗时间阶段的关键代谢改变涉及能量代谢、氧化应激反应、氨基酸代谢和肠道微生物群代谢。特别是,BYD 治疗 CH 的重要作用在于改善心脏能量生成和抗氧化能力。我们的研究通过监测动态代谢变化提供了对 BYD 治疗 CH 的整体观点,结果表明 BYD 可能作为治疗 CH 的潜在药物。